Trial Profile
A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Potassium bicarbonate/potassium citrate (Primary)
- Indications Cystinuria
- Focus Registrational; Therapeutic Use
- Acronyms CORAL
- Sponsors Advicenne
- 08 May 2023 Planned End Date changed from 1 Aug 2020 to 1 Jun 2025.
- 08 May 2023 Planned primary completion date changed from 1 Aug 2020 to 1 May 2025.
- 08 May 2023 Planned initiation date changed to 1 Mar 2024.